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roprote
CasaraAbstract—Optic nerve sheath diameter quantification by transbulbar B-mode sonography is a recently validated
technique, but its clinical relevance in relapse-free multiple sclerosis patients remains unexplored. In an
open-label, comparative, cross-sectional study, we aimed to assess possible differences between patients and
healthy controls in terms of optic nerve sheath diameter and its correlation with clinical/paraclinical parameters
in this disease. Sixty unselected relapse-free patients and 35 matched healthy controls underwent transbulbar
B-mode sonography. Patients underwent routine neurologic examination, brain magnetic resonance imaging
and visual evoked potential tests. The mean optic nerve sheath diameter 3 and 5 mm from the eyeball was 22–
25% lower in patients than controls and correlated with the Expanded Disability Status Scale (r 5 20.34,
p5 0.048, and r520.32, p5 0.042, respectively).We suggest that optic nerve sheath diameter quantified by trans-
bulbar B-mode sonography should be included in routine assessment of the disease as an extension of the neuro-
logic examination. (E-mail: dmsrrt@gmail.com)  2016 The Authors. Published by Elsevier Inc. on behalf of
World Federation for Ultrasound in Medicine & Biology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Early subclinical involvement of the afferent visual
pathway is described in most cases of multiple sclerosis
(MS) (Mogensen 1990) and is considered a functionally
eloquent system regarding the central nervous system
(CNS), as well as a clinical model of the disease
(Costello et al. 2006). The afferent visual pathway is
made up of tissue-specific substrates that sustain visual
function, including the retina, myelinated optic nerve,
chiasm, tracts, optic radiations and Brodmann area 17
of the cerebral cortex. Apart from the retina, the optic
nerve and other afferent visual pathway structures consist
of myelinated axon fibers, similar to those forming white
matter elsewhere in the brain, which makes them vulner-ddress correspondence to: Roberto DeMasi, Laboratory of Neu-
omics, Multiple Sclerosis Center, ‘‘F. Ferrari’’ Hospital, 73042
no-Lecce, Italy. E-mail: dmsrrt@gmail.com
3037able to inflammatory demyelinating injury in MS. Thus,
unlike the brain, the afferent visual pathway is regarded
as ‘‘eloquent,’’ because every lesion, however small, in-
duces clinical and/or readily detectable instrumental ab-
normalities. Moreover, previous pathologic studies have
reported that tissue-specific injury in the afferent visual
pathway reflects global CNS effects in MS patients
(Green et al. 2010). From this point of view, the optic
nerve can be seen as a clinical model of MS.
Perivenular infiltrative T cells with axonal loss and
reactive gliosis are common aspects involving the optic
nerves, retina and cerebral hemispheres (Costello et al.
2006). Moreover, neuroinflammatory-dependent reduc-
tion in the retinal nerve fiber layer (RNFL) is correlated
with brain and macular shrinkage, as well as optic nerve
involvement (Green et al. 2010).
Optic nerve sheath diameter (ONSD) quantification
by transbulbar B-mode sonography (TBS) is a non-
invasive technique recently validated among the general
Fig. 1. Significant inverse correlation between optic nerve
sheath diameter (ONSD) measured at 5 mm from the eyeball
and Expanded Disability Status Scale score in patients with
multiple sclerosis.
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amination (Bauerle et al. 2012, 2013). However, no
application concerning MS is reported in the literature,
so the predictive value of ONSD in this pathology is
still unexplored. In this sense, the optic nerve is very
interesting. Indeed, its derivation from the diencephalon
(specifically from the quadrigeminal plate) and its
oligodendroglial coating mark it as an external eversion
of the central nervous system.
Optic nerve (ON) fibers are myelinated in the orbital
part and the rest of the optic nerve, but they are unmyelin-
ated in the lamina cribrosa, starting from the last 3 mm
before their entry into the eyeball. The diencephalon is
a central brain structure, delimited from the deep gray
matter and crossed by sensitive and pyramidal/extrapyra-
midal tracts. Specifically, this strategic position near the
internal capsule is responsible for the early enlargement
of the third ventricle in MS, reflecting abiotrophic phe-
nomena in distant structures of hemispheric white matter
and the cortex (Minagar et al. 2013; Muller et al. 2013).
To summarize, the involvement of the ON in MS can be
considered an experimentum naturae, paradigmatic of
diffuse pathologic processes in the CNS.
The primary aim of this study was to assess any dif-
ferences between patients with MS and healthy control
subjects in terms of ONSD and, secondarily, to investi-
gate any correlation between ONSD and neurophysiolog-
ical, morphometric and clinically relevant parameters in a
random MS population.METHODS
In an open-label, comparative, cross-sectional study,
we investigated 60 unselected relapse-free MS patients
and 35 sex- and age-matched healthy control subjects,
for totals of 120 and 70 eyes, respectively. All patients un-
derwent TBS, which in patients was part of their clinical
examination. Within 24 h, brain magnetic resonance im-
aging (MRI) was conducted on the diseased patients, and
visual evoked potentials were measured. TBS was carried
out personally by the primary author of this work, a
neurophysiologist certified by the Italian neurosonology
society (Italian Society of Neurosonology and Brain Hae-
modynamics [SINSEC]).
AVivid 7 GE US system (GE Vingmed Ultrasound
AS, Horten, Norway) was used in accordance with
Bauerle et al. (2013, 2012). Briefly, with the 2.5- to 10-
MHz linear probe placed on the temporal part of the
closed upper eyelid, the optic nerve was depicted in a
transverse plane, revealing the papilla and the optic nerve
in its longitudinal course at 3 and 5 mm behind the
eyeball bilaterally. The distance between the external bor-
ders of the hyperechoic area surrounding the ON was
quantified as ONSD.P100 latency (P100 L) and amplitude (P100 A) were
calculated in accordance with Odom’s pattern-reversal
standard protocol. Briefly, visual evoked potentials
(VEPs) are visually evoked electrophysiologic signals ex-
tracted from the averaged electroencephalographic activ-
ity in the visual cortex, recorded from the scalp using an
active occipital electrode placed near the visual cortex.
The standard pattern stimulus is a high-contrast black
and white checkerboard with a square element size of
1 6 20 per side. For the pattern-reversal protocol, the
black and white checks change phase abruptly and repeat-
edly at a specified frequency (about two reversals per sec-
ond) evoking the P100 wave, whose amplitude and
latency reflect the functional integrity of the visual sys-
tem, including the retina, optic nerve, optic radiations
and occipital cortex.
All patients were positioned and imaged with a 1.5-
T Philips MR apparatus (180 mT/m) (Achieva, Philips
Medical Systems, Best, Netherlands), in accordance
with international guidelines (Miller et al. 1991).
Briefly, the acquisition sequence types were SE T1–
TSE T1 MT–BRAIN VIEW FLAIR 3-D; acquisition
time 2.170–3.070–4.140; field of view 230 3 183 mm
AX–250 3 250 FLAIR SAG–180-200 3 180 mm
COR MT; orientation: TRA–COR–TRA; alignment:
TRA–COR–TRA; and voxel size: 0.89/0.88/4–0.56/
0.56/4–0.31/0.31/0.6, respectively. TR was 450–614–
4800; TE was 15–12–307; and TI was –/–/1660. The
flip angle was 69–90–/, and the NEX was 1–2–2.
SENSE parallel imaging method and contrast enhance-
ment (Gadovist single dose, 10 min post-
administration) were used.
Table 1. Demographic and clinical characteristics of the study population*
Parameter Patients Controls p
N 65 35
Age (y) 39.4 6 2.81y 38.5 6 1.90
Female-to-male ratio 1.27 1.30
Disease duration (y) 12 (9.51–14.61) —
Expanded Disability Status Scale score 3.5 (2.50–3.51) —
Optic nerve sheath diameter (mm)
At 3 mm 0.49 6 0.074 (0.45–0.52) 0.65 6 0.077 (0.62–0.68) ,0.001
At 5 mm 0.57 6 0.064 (0.55–0.60) 0.73 6 0.092 (0.70–0.78) ,0.001
P100 amplitude (mV) 5.22 6 2.60 (4.33–6.10) —
P100 latency (ms) 141.90 6 16.29 (136.81–148.10) —
Myelination index 0.84 (0.81–0.86) 0.89 (0.86–0.90) 0.014
* Note that optic nerve sheath diameter at both 3 and 5 mm from the eyeball and myelination index were found to be lower in patients than in controls.
The Wilcoxon–Mann–Whitney test was applied to the difference between means.
y Values are given as the mean or mean 6 standard deviation, with the 95% confidence interval in parentheses.
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nax’’ software (created by the Analysis Group, FMRIB,
Oxford, UK), to determine the brain parenchymal frac-
tion (BPF), the ‘‘MIPAV’’ (National Institutes of Health
Center for Information Technology Rockville, MD,
USA) for calculating the T1 and T2 lesion loads (T1
LL, T2 LL) and the ‘‘SPM12’’ (Functional Imaging Lab-
oratory, Wellcome Trust Centre for Neuroimaging, Insti-
tute of Neurology, London, UK) for calculating the gray/
white matter fractions (GMF, WMF), CSF ventricular
volume (CSFV) and peripheral gray matter fraction
(PGMF).
The clinical parameters considered were the
Expanded Disability Status Scale (EDSS) score and
sub-scores and disease duration (DD). Developed by
Kurtzke in 1983, the EDSS is a universal scale for
quantifying neurologic impairment in multiple scle-
rosis (Kurtzke 1983). This method numerically quan-
tifies overall disability with reference to the eight
functional systems (pyramidal, sensitive, cerebellar,
etc.) and allows neurologists to assign a functional sys-
tem score (the so-called functional sub-score) to eachTable 2. Inferential statistics: Correlations*
Parameter r p
Optic nerve sheath diameter at 3 mm
EDSS 0.31 0.048*
Pyramidal EDSS sub-score 20.36 0.059
Sensitive EDSS sub-score 20.35 0.058
Optic nerve sheath diameter at 5 mm
EDSS 20.32 0.042*
Pyramidal EDSS sub-score 20.34 0.061
Sensitive EDSS sub-score 20.32 0.060
P100 amplitude
EDSS 20.41 0.002*
P100 latency
EDSS 0.41 #0.011*
Peripheral gray matter fraction 20.41 0.017*
EDSS 5 Expanded Disability Status Scale.
* Significant correlations are indicated.of them. Co-morbidity, including ophthalmic and
toxic-deficiency diseases, entailed exclusion from the
study. Also excluded were patients affected by retro-
bulbar optic neuritis.
The Wilcoxon–Mann–Whitney test was applied to
the difference between means; the Spearman rank test
was used to assess the magnitude of correlation between
ONSD and other variables; and cluster analysis was used
to determine the distribution of ONSD and other variables
among the MSs patients. Finally, we used the coefficient
of variation (COV) for determining the intra-observer
reliability of ONSD, calculated on the basis of test–retest
evaluations of the entire study population. Thus, every
eyeball was examined twice, at the start of the study
and within 1½ mo after the first assessment. These pro-
cedures were approved by the local ethics committee
and all participants in the study signed written informed
consent forms.RESULTS
No statistical difference was found between the
mean age of MS patients (39.4 y, SD 2.81) and healthy
controls (38.5 y, SD 1.90); the female-to-male sex ratios
were respectively 1.27 and 1.3. Mean DD was 12 y (95%
confidence interval [CI]5 9.51–14.61). Mean EDSS was
3.5, ranging from 1.0 to 6.5 (95% CI 5 2.50–3.51). The
mean COVof ONSD was 0.065. Mean ONSD in patients
at 3 and 5 mm from the eyeball was respectively 0.49 mm
(95% CI 5 0.45–0.52, SD 0.074) and 0.57 mm (95%
CI5 0.55–0.60, SD 0.064). Mean ONSD in healthy con-
trols at 3 and 5 mm from the eyeball was respectively
0.65 mm (95% CI 5 0.62–0.68, SD 0.077) and
0.73 mm (95% CI5 0.70–0.78, SD 0.092). These differ-
ences between diseased patients and healthy subjects
were highly significant. Specifically, at both 3 and
5 mm, the ONSD was found to be smaller in patients
than in healthy controls (p , 0.001 in both cases).
Fig. 2. Transbulbar B-mode sonography of the optic nerve sheath diameter (ONSD) of a healthy subject (a) compared
with that of a patient with multiple sclerosis (b). The distance between the external borders of the hyper-echoic area sur-
rounding the optic nerve was quantified as ONSD. Lines 4 and 2 indicate ONSD at 3 and 5 mm from the eyeball, respec-
tively. Note the smaller size of the ONSD in the patient with multiple sclerosis at both 3 and 5 mm from the eyeball.
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negligible in all cases (0.433 # p # 0.615). Thus, for
simplicity, from now on ONSD will refer to the mean
inter-side value. The same criterion was used for P100
A (mean 5 5.22 mV, 95% CI 5 4.33–6.10, SD 2.60)
and P100 L (mean 5 141.90 ms, 95% CI 5 136.81–
148.10, SD 16.29). Moreover, we noted smaller ONSDs
in healthy controls at 3 mm than at 5 mm (p , 0.001),
but no significant difference between ONSDs at 3 and
5 mm in patients. An inverse correlation was found be-
tween the ONSD and the EDSS score, at both 3 mm
and 5 mm, in patients (r 5 20.31, p 5 0.048, and
r 5 20.32, p 5 0.042 respectively) (Fig. 1). In addition,
at both 3 and 5 mm, ONSD in patients correlated
inversely with both the pyramidal (20.36 # r #
20.34, 0.059 # p # 0.061) and sensitive (20.35 # r
#20.32, 0.058# p# 0.060) EDSS sub-scores. No cor-
relation was found between ONSD in patients (at either 3
or 5 mm) and P100 A, P100 L, T1 LL, T2 LL, BPF, GMF,
WMF, CSFVor PGMF.
We also considered the ratio of ONSD at 3 mm to
ONSD at 5 mm, also called the myelination index (MI),
which for the healthy controls was 0.89 (95% CI 5 0.86–
0.90) and for patients 0.84 (95% CI5 0.81–0.86). The MI
of healthy controls was significantly higher than that of pa-
tients (p5 0.014). The demographic and clinical features of
patients and control subjects are summarized in Table 1.
Statistical clustering of patients revealed a group
with low P100 A and high P100 L (respectively 3.93
and 165.42, p 5 0.040) and a group with high P100 A
and low P100 L (respectively 5.73 and 132.71,
p , 0.001), but no clustering of ONSD in patients was
identified at either 3 or 5 mm.We found an inverse correlation between P100 A
and EDSS (r520.41, p5 0.002) and a direct correlation
between P100 L and EDSS (r 5 0.41, p # 0.011). Inter-
estingly, we found an inverse correlation between right
P100 L and PGMF (r 5 20.41, p 5 0.017). Table 2 out-
lines the significant correlations between ONSD and clin-
ical variables, as well as between P100 latency and
clinical/paraclinical parameters.DISCUSSION AND CONCLUSIONS
In a comparative study of a relapse-free random MS
population and matched healthy controls we found
several differences in ONSD, which proved to be signif-
icantly smaller in the MS group, at both 3 and 5 mm from
the eyeball (Figs. 2 and 3). The gap between the two
groups was 22–25% at corresponding levels. Moreover,
there was no statistical difference in MS patients
between ONSD at 3 mm and ONSD at 5 mm, unlike in
the healthy control group, in which ONSD was
significantly wider at 5 mm than at 3 mm from the
eyeball. This condition can only be explained with
reference to a chronic depletion of axons in MS and
physiologically lower myelination, or no myelination at
all, of the ON in the tract just behind the eyelid.
To confirm this, we considered the MI, calculated as
the ratio of ONSD at 3 mm to ONSD at 5 mm, which for
the healthy controls was 0.89. The biological basis of MI
is the CNS structure, in which almost all axons with di-
ameters greater than 0.2 mm are myelinated. The ratio
of axon diameter to the diameter of the total fiber (axon
and myelin), the so called G ratio, is 0.90, which is main-
tained regardless of the axon caliber (FitzGibbon and
Fig. 3. Magnetic resonance images of the optic nerve sheath diameter (ONSD) of a healthy control (a, c) compared with
those of a patient with multiple sclerosis (b, d). (a, b) Axial representations. (c, d) Transverse representations. Note the
smaller ONSD in the patient with multiple sclerosis, in both the axial and transverse sections. All images refer to T2/T1
bFFE sequences, acquired with SENSE Head 8 channels.
Transbulbar B-mode US in MS d R. DE MASI et al. 3041Nestorovski, 2013) and is very similar to 0.89. The MI of
patients was 0.84. Therefore, given that MI in healthy
controls is significantly higher than that in patients
(p 5 0.014), the smaller ONSD in patients cannot be
attributed to anything other than axonal loss or shrinkage
(95–96%) and demyelination (4–5%). Surprisingly, not
only did we find no correlation between ONSD and the
neurophysiologic parameters of P100, but also no corre-
spondence between P100 clusters and ONSD.
A similar lack of correlation was observed between
ONSD and both the MRI lesion burden and whole-brain
atrophy, as well as the gray and white matter volumes.
This can be explained by considering the anatomic het-
erogeneity of the visual system, in which bidirectional
Wallerian degeneration can occur in the afferent visual
pathway and retrograde or trans-synaptic degeneration
can occur in the posterior visual pathway (Kanamori
et al., 2012), making it difficult to judge which factor ac-
counts for the simple measure of ON thickness. Specif-ically, Wallerian degeneration is a consequence of the
separation of the distal axon from its metabolic support
within the cell body; retrograde or trans-synaptic degen-
eration is a consequence of growth-factor deprivation
from the post-synaptic target, particularly in the lateral
geniculate bodies, where the loss of visual afferences
takes place. These considerations clearly do not apply
to the EDSS scores. The latter are inversely correlated
with ONSD, providing a global measure of function
that is closely linked to the tropism of the long routes.
The magnitude of this correlation is similar to known cor-
relations between lesion burden (T1 LL or T2 LL) and
EDSS. Unlike ONSD, PGMF correlated with P100 pa-
rameters because of the cortical genesis of their potential.
The cross-sectional perspective and single-observer
assessment of TBS may represent weaknesses of the pre-
sent study. Therefore, the inter-observer reliability of
ONSD and its applicability in a longitudinal study are still
to be verified.
3042 Ultrasound in Medicine and Biology Volume 42, Number 12, 2016In summary, we found that ONSDmeasured by TBS
is significantly lower in MS patients. This parameter ex-
presses subclinical axonal loss over time and is not corre-
lated with neurophysiologic or morphometric values, or
with disease duration, but only with neurologic disability
expressed as EDSS. The good reliability of ONSD cor-
roborates these observations.
Given these considerations, we suggest ONSD
measured by TBS can be used for the detection of optic
nerve damage and should be adopted as an extension of
routine clinical assessment for MS.
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